ResearcherTohoku UniversityNo recent work listed
Tetsuya Terasaki
Matched on ORCID iD 0000-0002-6332-7575; OpenAlex author ID A5026158271. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 6)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 20
2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers
Papers 6
- All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kina… Last author DOI 10.1016/j.ejps.2017.02.021↗
- MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction Between Pancreatic Cancer Cells and Ste… Last author DOI 10.1097/mpa.0000000000000778↗
- Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-B… Last author DOI 10.1371/journal.pone.0161009↗
- Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcita… Last author DOI 10.1021/acs.molpharmaceut.5b00282↗
- Quantitative targeted absolute proteomics-based large-scale quantification of proline-hydroxylated α-fibrinogen in plasma for pancreatic cancer diagnosis. Last author DOI 10.1021/pr3008144↗
- Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metab… Last author DOI 10.1007/s11095-012-0728-2↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michiaki Unno · 4 shared papers, 2012–2017 · strength 0.22
- Paper All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating … DOI 10.1016/j.ejps.2017.02.021↗
- Paper MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction… DOI 10.1097/mpa.0000000000000778↗
- Paper Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Fre… DOI 10.1021/acs.molpharmaceut.5b00282↗
- Kei Kawaguchi · 3 shared papers, 2012–2017 · strength 0.14
- Paper MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction… DOI 10.1097/mpa.0000000000000778↗
- Paper Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Fre… DOI 10.1021/acs.molpharmaceut.5b00282↗
- Paper Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer… DOI 10.1007/s11095-012-0728-2↗
- Fuyuhiko Motoi · 3 shared papers, 2012–2017 · strength 0.14
- Paper MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction… DOI 10.1097/mpa.0000000000000778↗
- Paper Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Fre… DOI 10.1021/acs.molpharmaceut.5b00282↗
- Paper Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer… DOI 10.1007/s11095-012-0728-2↗
- Ken Ohmine · 3 shared papers, 2012–2015 · strength 0.12
- Paper Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Fre… DOI 10.1021/acs.molpharmaceut.5b00282↗
- Paper Quantitative targeted absolute proteomics-based large-scale quantification of proline-hydroxylated α-fibrinogen in plas… DOI 10.1021/pr3008144↗
- Paper Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer… DOI 10.1007/s11095-012-0728-2↗
- Shinichi Egawa · 2 shared papers, 2012–2017 · strength 0.09
- Paper MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction… DOI 10.1097/mpa.0000000000000778↗
- Paper Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer… DOI 10.1007/s11095-012-0728-2↗
- Toshihiro Yoneyama · 2 shared papers, 2013–2016 · strength 0.08
- Paper Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Comb… DOI 10.1371/journal.pone.0161009↗
- Paper Quantitative targeted absolute proteomics-based large-scale quantification of proline-hydroxylated α-fibrinogen in plas… DOI 10.1021/pr3008144↗
- Tesshi Yamada · 2 shared papers, 2013–2016 · strength 0.08
- Paper Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Comb… DOI 10.1371/journal.pone.0161009↗
- Paper Quantitative targeted absolute proteomics-based large-scale quantification of proline-hydroxylated α-fibrinogen in plas… DOI 10.1021/pr3008144↗
- Koetsu Inoue · 1 shared paper, 2017 · strength 0.07
- Hiroki Kuroda · 1 shared paper, 2017 · strength 0.07
- Shuhei Kawasaki · 1 shared paper, 2017 · strength 0.06
- Yu Katayose · 1 shared paper, 2017 · strength 0.06
- Koetsu Inoue · 1 shared paper, 2017 · strength 0.06
- Daisuke Douchi · 1 shared paper, 2017 · strength 0.06
- Shoji Nakamori · 1 shared paper, 2016 · strength 0.04
- Tomoo Kosuge · 1 shared paper, 2016 · strength 0.04
- Tatsuya Ioka · 1 shared paper, 2016 · strength 0.04
- Naohiro Sata · 1 shared paper, 2016 · strength 0.04
- Akihiko Tsuchida · 1 shared paper, 2016 · strength 0.04
- Takuji Okusaka · 1 shared paper, 2016 · strength 0.04
- Kazufumi Honda · 1 shared paper, 2016 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.